compounded semaglutide enforcement news today Troubling Findings in Study of GLP-1 Compounders Omzo GLP-1 Review 2026: Is

The material from Koi is a research-grade lyophilized peptide vial with analytical documentation (HPLC, LC-MS, endotoxin) built around in vitro laboratory use, not patient-directed compounding, dispensing, or any clinical workflow

In 2026, the FDA approved a new higher dose of Wegovy that may help some patients lose more weight

Download the Straight Arrow app today to get the stories that matter free from manipulation, bias or agenda. Point phone camera here The promising results have more and more people vying for the experimental drug, even if it has not yet been deemed safe and effective by the FDA

2025 Aug 4;12(8):e01789

A non-randomized trial found that amifostine protected against cisplatin-induced serious hearing loss in average-risk but not high-risk patients with medulloblastoma (a type of brain tumor) (Gurney 2014)

Now, let me be clear from the start